title: The HER2- and heregulin β1 (HRG)-inducible TNFR superfamily member Fn14 promotes HRG-driven breast cancer cell migration, invasion, and MMP9 expression.
abstract: HER2 overexpression occurs in 15% to 20% of all breast cancers and is associated with increased metastatic potential and poor patient survival. Abnormal HER2 activation, either through HER2 overexpression or heregulin (HRG):HER3 binding, elicits the formation of potent HER2-HER3 heterodimers and drives breast cancer cell growth and metastasis. In a previous study, we found that fibroblast growth factor-inducible 14 (Fn14), a member of the TNF receptor superfamily, was frequently overexpressed in human HER2+ breast tumors. We report here that HER2 and Fn14 are also coexpressed in mammary tumors that develop in two different transgenic mouse models of breast cancer. In consideration of these findings, we investigated whether HER2 activation in breast cancer cells could directly induce Fn14 gene expression. We found that transient or stable transfection of MCF7 cells with a HER2 expression plasmid increased Fn14 protein levels. Also, HRG1-β1 treatment of MCF7 cells transiently induced Fn14 mRNA and protein expression. Both the HER2- and HRG1-β1-induced increase in Fn14 expression in MCF7 cells as well as basal Fn14 expression in HER2 gene-amplified AU565 cells could be reduced by HER2 kinase inhibition with lapatinib or combined HER2 and HER3 depletion using siRNA. We also report that Fn14-depleted, HER2-overexpressing MCF7 cells have reduced basal cell migration capacity and reduced HRG1-β1-stimulated cell migration, invasion, and matrix metalloproteinase (MMP)-9 expression. Together, these results indicate that Fn14 may be an important downstream regulator of HER2/HER3-driven breast cancer cell migration and invasion.
authors: Department of Surgery, Center for Vascular and Inflammatory Diseases, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA.
authors: Kaushal
authors: K
authors: Asrani
authors: Ruth A
authors: RA
authors: Keri
authors: Rebeca
authors: R
authors: Galisteo
authors: Sharron A N
authors: SA
authors: Brown
authors: Sarah J
authors: SJ
authors: Morgan
authors: Arundhati
authors: A
authors: Ghosh
authors: Nhan L
authors: NL
authors: Tran
authors: Jeffrey A
authors: JA
authors: Winkles
mesh_terms: D000818:Animals; D001943:Breast Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D002465:Cell Movement / Q000502:physiology*; D004195:Disease Models, Animal; D005260:Female; D006801:Humans; D008297:Male; D020780:Matrix Metalloproteinase 9 / Q000096:biosynthesis* / Q000235:genetics / Q000378:metabolism; D051379:Mice; D008822:Mice, Transgenic; D020890:Neuregulin-1 / Q000378:metabolism / Q000494:pharmacology*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics / Q000378:metabolism*; D018124:Receptors, Tumor Necrosis Factor / Q000096:biosynthesis*; D000074050:TWEAK Receptor; D014162:Transfection
chemical_list: D020780:Matrix Metalloproteinase 9; D020890:Neuregulin-1; D018719:Erb-b2 Receptor Tyrosine Kinases; D018124:Receptors, Tumor Necrosis Factor; D000074050:TWEAK Receptor; C000613297:TNFRSF12A protein, human; C000613299:Tnfrsf12a protein, mouse; C087230:heregulin beta1
references: Mol Cancer Ther. 2009 Aug;8(8):2152-62
references: 19671734
references: Oncogene. 2005 Aug 4;24(33):5173-90
references: 15897883
references: Cancer Res. 2008 Jul 15;68(14):5878-87
references: 18632642
references: Mol Cancer Res. 2008 May;6(5):725-34
references: 18505918
references: Cancer Lett. 2012 Jan 1;314(1):73-81
references: 21993017
references: Clin Cancer Res. 2008 Nov 1;14(21):6730-4
references: 18980964
references: Cancer Res. 2006 Feb 1;66(3):1418-26
references: 16452197
references: Cancer Res. 2005 Jun 15;65(12):5380-9
references: 15958587
references: J Cell Biol. 2005 Nov 7;171(3):505-16
references: 16275754
references: Clin Cancer Res. 2008 Jun 1;14(11):3237-41
references: 18519747
references: EMBO J. 1999 Apr 15;18(8):2149-64
references: 10205169
references: EMBO J. 1995 Sep 1;14(17):4267-75
references: 7556068
references: Nat Rev Drug Discov. 2007 Jun;6(6):431-2
references: 17633789
references: J Cancer Res Clin Oncol. 2013 Feb;139(2):315-25
references: 23073510
references: Cancer Res. 2009 Apr 1;69(7):3221-7
references: 19293185
references: Oncogene. 2001 Sep 27;20(43):6215-24
references: 11593430
references: Oncogene. 2007 Oct 4;26(45):6469-87
references: 17471238
references: Proc Natl Acad Sci U S A. 1992 Nov 15;89(22):10578-82
references: 1359541
references: Biochem J. 2003 Apr 15;371(Pt 2):395-403
references: 12529173
references: Cell. 2010 Apr 2;141(1):52-67
references: 20371345
references: Carcinogenesis. 2011 Nov;32(11):1589-96
references: 21828059
references: J Biol Chem. 1998 Oct 23;273(43):28238-46
references: 9774445
references: CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29
references: 22237781
references: Clin Cancer Res. 2009 Dec 15;15(24):7479-7491
references: 20008848
references: Cancer Res. 2004 Dec 15;64(24):8968-72
references: 15604260
references: Mol Cell Biochem. 2008 Nov;318(1-2):73-9
references: 18600430
references: Mol Cancer Res. 2003 Jan;1(3):165-75
references: 12556556
references: Cell. 2011 Nov 23;147(5):992-1009
references: 22118458
references: Nat Rev Drug Discov. 2008 May;7(5):411-25
references: 18404150
references: Oncogene. 2001 Dec 6;20(56):8066-74
references: 11781819
references: J Biol Chem. 2005 Feb 4;280(5):3483-92
references: 15611130
references: J Biol Chem. 2010 Jun 4;285(23):17432-41
references: 20385556
references: Exp Cell Res. 2003 Mar 10;284(1):54-65
references: 12648465
references: Clin Cancer Res. 2010 Mar 1;16(5):1373-83
references: 20179223
references: Oncogene. 2005 Apr 14;24(16):2613-24
references: 15735761
references: Am J Pathol. 2003 Nov;163(5):2113-26
references: 14578209
references: Cancer Cell. 2002 Aug;2(2):127-37
references: 12204533
references: Am J Pathol. 2012 Jul;181(1):111-20
references: 22634180
references: Br J Cancer. 1998 Nov;78(10):1385-90
references: 9823984
references: Cancer Res. 2006 Oct 1;66(19):9535-42
references: 17018610
references: Mol Cancer Ther. 2008 May;7(5):1195-206
references: 18483307
references: Biol Pharm Bull. 2009 May;32(5):899-904
references: 19420761
references: Nature. 2007 Jan 25;445(7126):437-41
references: 17206155
references: Cancer Cell. 2006 Dec;10(6):515-27
references: 17157791
references: Am J Pathol. 2005 Feb;166(2):511-20
references: 15681834
references: Mol Cell Biol. 1992 Mar;12(3):954-61
references: 1312220
references: Cancer Res. 2007 Feb 15;67(4):1487-93
references: 17308086
references: Immunol Rev. 2011 Nov;244(1):99-114
references: 22017434
references: Cancer Lett. 2006 Apr 8;235(1):11-7
references: 15885893
references: Oncogene. 2010 Feb 25;29(8):1238-48
references: 19946332